| Hayley Wurtz Hunt, MD | |
|
11511 Ne 10th St, Bellevue, WA 98004-8578 | |
| (425) 502-3000 | |
| (844) 620-1839 |
| Full Name | Hayley Wurtz Hunt |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 10 Years |
| Location | 11511 Ne 10th St, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649697863 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD60847078 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
People suffering from post-traumatic stress disorder (PTSD) face a greater risk of cardiovascular disease and death. A new study involving a comprehensive review of the medical literature shows that PTSD also increases an individual's risk of metabolic syndrome.
Scientists at Schepens Eye Research Institute, an affiliate of Harvard Medical School, say a visual aid they invented promises to improve the visual abilities of people with tunnel vision.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Primary care doctors are not quick to prescribe antihypertensive medication to young people even after an average of 20 months of high blood pressure. Young adults who are white, male, not on Medicaid and not frequent clinic visitors are especially less likely to receive medication. These are the results of a study by a research team at the University of Wisconsin School of Medicine and Public Health in the United States led by Heather Johnson.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
People suffering from post-traumatic stress disorder (PTSD) face a greater risk of cardiovascular disease and death. A new study involving a comprehensive review of the medical literature shows that PTSD also increases an individual's risk of metabolic syndrome.
Scientists at Schepens Eye Research Institute, an affiliate of Harvard Medical School, say a visual aid they invented promises to improve the visual abilities of people with tunnel vision.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Primary care doctors are not quick to prescribe antihypertensive medication to young people even after an average of 20 months of high blood pressure. Young adults who are white, male, not on Medicaid and not frequent clinic visitors are especially less likely to receive medication. These are the results of a study by a research team at the University of Wisconsin School of Medicine and Public Health in the United States led by Heather Johnson.
› Verified 1 days ago
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689612954 PECOS PAC ID: 0244138196 Enrollment ID: O20031230000187 |
News Archive
People suffering from post-traumatic stress disorder (PTSD) face a greater risk of cardiovascular disease and death. A new study involving a comprehensive review of the medical literature shows that PTSD also increases an individual's risk of metabolic syndrome.
Scientists at Schepens Eye Research Institute, an affiliate of Harvard Medical School, say a visual aid they invented promises to improve the visual abilities of people with tunnel vision.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Primary care doctors are not quick to prescribe antihypertensive medication to young people even after an average of 20 months of high blood pressure. Young adults who are white, male, not on Medicaid and not frequent clinic visitors are especially less likely to receive medication. These are the results of a study by a research team at the University of Wisconsin School of Medicine and Public Health in the United States led by Heather Johnson.
› Verified 1 days ago
| Entity Name | Valley Medical Group-renton |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619209574 PECOS PAC ID: 4183753965 Enrollment ID: O20100604000113 |
News Archive
People suffering from post-traumatic stress disorder (PTSD) face a greater risk of cardiovascular disease and death. A new study involving a comprehensive review of the medical literature shows that PTSD also increases an individual's risk of metabolic syndrome.
Scientists at Schepens Eye Research Institute, an affiliate of Harvard Medical School, say a visual aid they invented promises to improve the visual abilities of people with tunnel vision.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Primary care doctors are not quick to prescribe antihypertensive medication to young people even after an average of 20 months of high blood pressure. Young adults who are white, male, not on Medicaid and not frequent clinic visitors are especially less likely to receive medication. These are the results of a study by a research team at the University of Wisconsin School of Medicine and Public Health in the United States led by Heather Johnson.
› Verified 1 days ago
| Entity Name | Obhg Washington Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962729525 PECOS PAC ID: 0345364642 Enrollment ID: O20100823001087 |
News Archive
People suffering from post-traumatic stress disorder (PTSD) face a greater risk of cardiovascular disease and death. A new study involving a comprehensive review of the medical literature shows that PTSD also increases an individual's risk of metabolic syndrome.
Scientists at Schepens Eye Research Institute, an affiliate of Harvard Medical School, say a visual aid they invented promises to improve the visual abilities of people with tunnel vision.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Primary care doctors are not quick to prescribe antihypertensive medication to young people even after an average of 20 months of high blood pressure. Young adults who are white, male, not on Medicaid and not frequent clinic visitors are especially less likely to receive medication. These are the results of a study by a research team at the University of Wisconsin School of Medicine and Public Health in the United States led by Heather Johnson.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hayley Wurtz Hunt, MD 11511 Ne 10th St, Bellevue, WA 98004-8578 Ph: (425) 502-3000 | Hayley Wurtz Hunt, MD 11511 Ne 10th St, Bellevue, WA 98004-8578 Ph: (425) 502-3000 |
News Archive
People suffering from post-traumatic stress disorder (PTSD) face a greater risk of cardiovascular disease and death. A new study involving a comprehensive review of the medical literature shows that PTSD also increases an individual's risk of metabolic syndrome.
Scientists at Schepens Eye Research Institute, an affiliate of Harvard Medical School, say a visual aid they invented promises to improve the visual abilities of people with tunnel vision.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
Primary care doctors are not quick to prescribe antihypertensive medication to young people even after an average of 20 months of high blood pressure. Young adults who are white, male, not on Medicaid and not frequent clinic visitors are especially less likely to receive medication. These are the results of a study by a research team at the University of Wisconsin School of Medicine and Public Health in the United States led by Heather Johnson.
› Verified 1 days ago
Dr. Jill Rosetta Varni, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 9923 Lake Washington Blvd Ne, Bellevue, WA 98004 Phone: 425-505-2159 | |
Dr. Roberta Haynes De Regt, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1135 116th Ave Ne, Suite 320, Bellevue, WA 98004 Phone: 425-688-8111 | |
Dr. Sarah Linse Bienenfeld, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1231 116th Ave Ne Ste 950, Bellevue, WA 98004 Phone: 425-454-6674 Fax: 425-646-5198 | |
Dr. Mark S Fan, MD Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 1515 116th Ave Ne Ste 205, Bellevue, WA 98004 Phone: 310-866-3707 Fax: 425-999-4858 | |
Dr. Natalia Allison Dvorak, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1600 116th Ave Ne, #104, Bellevue, WA 98004 Phone: 323-857-3871 | |
Dr. Daniel Gavrila, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite #320, Bellevue, WA 98004 Phone: 425-688-8111 | |
Sara A Durkee, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 |